Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.
As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up ...
Meiji Seika Pharma invests in MPM BioImpact's new technology and virology strategy to expand early-stage opportunities and ...
The global proteinase K market is projected to grow from US$ 27.5 million in 2023 to US$ 43.9 million by 2033, at a CAGR of 4 ...
Increases speed to market for drug developers working on nucleic acid therapeutics.
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
News Medical on MSN14d
Complex interactions between nucleic acid sensors and enzymes in immune cells explainedAdenosine deaminase 2 (ADA2) has been identified as a regulator of toll-like receptor 9 (TLR9) activation in response to nucleic acids, according to a recent study.
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/97.TRc4SPmX.js ...
Evonik has partnered with ST Pharm to enhance its RNA and nucleic acid therapeutic services, combining ST Pharm's expertise in customized nucleic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback